Background & Aims Crohn's disease (CD) patients included in the Tailored Treatment With
Infliximab for Active Crohn's Disease (TAILORIX) trial started infliximab in combination with …

Background: Iron deficiency anemia (IDA) is a common extraintestinal manifestation of
inflammatory bowel disease (IBD), affecting around one-third of patients. Objective: To …

Moving towards more patient-centred clinical trials in IBD | Nature Reviews Gastroenterology
& Hepatology Skip to main content Thank you for visiting nature.com. You are using a browser …

Background Evidence for the effects of dietary fiber on adverse outcomes in individuals with
inflammatory bowel disease (IBD) is insufficient and controversial. Objectives We aimed to …

Inflammatory bowel disease (IBD) is an emerging global disease characterised by chronic
inflammation of the gastrointestinal tract. However, IBD is also manifested by several …

Despite improved therapeutic strategies and expanding therapeutic targets, inflammatory
bowel disease remains a disabling disease with potential to progress and lead to …

ABSTRACT BACKGROUND & AIMS Upadacitinib, an oral Janus kinase inhibitor, achieved
significantly higher rates of clinical remission and endoscopic response vs placebo during …

Inflammatory bowel disease (IBD) is a chronic relapsing gastrointestinal disorder, while the
treatment effect is not satisfactory. Immune responsive gene 1 (IRG1) is a highly expressed …

Inflammatory Bowel Diseases had their first peak in incidence in countries in North America,
Europe, and Oceania and are currently experiencing a new acceleration in incidence …

Background We evaluated the health-related quality of life (HRQoL) benefits of upadacitinib
(UPA) induction and maintenance treatment in a phase 3 study of patients with ulcerative …